| 1483 |
National Cancer Institute |
Html |
en |
Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of Kaposi sarcoma. |
| classic ks | 0.718451 |
| azathioprine developed KS | 0.600594 |
| skin surface area | 0.47235 |
| systemic lesions | 0.493932 |
| indolent course | 0.470841 |
| mucocutaneous lesions | 0.512302 |
| renal transplant | 0.501016 |
| visceral lesions | 0.497461 |
| KS involvement | 0.562512 |
| KS incidence | 0.560945 |
| KS lesions | 0.599331 |
| Pleuropulmonary KS | 0.5556 |
| HIV disease patients | 0.521452 |
| relatively common neoplasm | 0.471596 |
| widespread mucocutaneous lesions | 0.507995 |
| patients | 0.634408 |
| renal transplant patient | 0.470087 |
| drug-resistant HIV strains | 0.474114 |
| immunosuppressive therapy | 0.478552 |
| lymph nodes | 0.596884 |
| renal transplant patients | 0.496667 |
| gastrointestinal tract | 0.58589 |
| rare disease | 0.483334 |
| classic KS tumor | 0.622697 |
| detectable visceral organ | 0.475328 |
|
| iatrogenically immunosuppressed patients | 0.494142 |
| numerous lesions | 0.474766 |
| opportunistic infections | 0.508602 |
| HIV disease | 0.544402 |
| gastrointestinal tract disease | 0.488821 |
| KS treatment | 0.552981 |
| innumerable skin lesions | 0.514662 |
| standard tumor assessment | 0.472883 |
| visceral organ involvement | 0.584749 |
| disease | 0.576658 |
| African KS | 0.57237 |
| AIDS patients | 0.479351 |
| epidemic KS die | 0.595228 |
| classical KS | 0.550709 |
| rapidly progressive tumor | 0.472892 |
| KS | 0.931586 |
| Classic KS tumors | 0.625414 |
| generalized KS | 0.572002 |
| skin disease | 0.482408 |
| epidemic KS | 0.750866 |
| skin lesions | 0.586652 |
| additional lesions | 0.488289 |
| nodular skin lesions | 0.53343 |
| biopsy-proven KS | 0.558149 |
|
CLICK HERE |
| 1486 |
National Cancer Institute |
Html |
en |
Melanoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of melanoma. |
| temozolomide versus dacarbazine | 0.706064 |
| standard therapy arm | 0.513108 |
| individual treatment sections | 0.538046 |
| single-agent inhibitor | 0.443006 |
| BRAF-mutated metastatic melanoma | 0.711751 |
| Val600 BRAF-mutant melanoma | 0.627182 |
| drug targets | 0.434691 |
| clinical trial design | 0.573658 |
| Drug Administration | 0.434687 |
| primary endpoint | 0.423708 |
| DTIC | 0.525789 |
| MEK inhibitor | 0.453277 |
| rare CRs | 0.424667 |
| active moiety | 0.422545 |
| randomized trials. | 0.46852 |
| BRAF-mutant subtype | 0.57943 |
| phase III study | 0.513517 |
| important option | 0.423407 |
| phase iii trials | 0.549837 |
| oral alkylating agent | 0.523779 |
| clinical trials | 0.434562 |
| V600 mutant melanoma | 0.640167 |
| sample size | 0.421859 |
|
| palliative radiation therapy | 0.502761 |
| multicenter trial | 0.445549 |
| temozolomide group | 0.594959 |
| multiagent chemotherapy | 0.434715 |
| randomized trial | 0.479926 |
| first-line vs. | 0.432084 |
| Clin Oncol | 0.536064 |
| Combination therapies | 0.426982 |
| genomic subtypes | 0.583162 |
| superior OS | 0.42215 |
| recent registration trials | 0.531572 |
| guide clinical decision-making | 0.554726 |
| Grob JJ | 0.535846 |
| High-dose recombinant interleukin | 0.518234 |
| ECOG PS | 0.423492 |
| randomised phase | 0.46148 |
| metastatic melanoma | 0.981501 |
| previously untreated patients | 0.74564 |
| primary endpoints | 0.427198 |
| metastatic malignant melanoma | 0.829145 |
| stage IV melanoma | 0.540818 |
| U.S. Food | 0.438775 |
|
CLICK HERE |
| 1614 |
National Cancer Institute |
Html |
en |
Small Intestine Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of small intestine cancer. |
| treatment | 0.474663 |
| cancer treatment | 0.28121 |
| general information | 0.207525 |
| biologic therapy | 0.208552 |
| new cancer treatments | 0.211372 |
| NCI-supported cancer | 0.201612 |
| cancer cells | 0.363757 |
| small intestine leiomyosarcoma | 0.321766 |
| body | 0.259153 |
| Cancer Information Service | 0.211251 |
| PDQ cancer information | 0.323637 |
| clinical trial search | 0.240948 |
| intestine cancer spreads | 0.326211 |
| treatment clinical trials | 0.247389 |
| National Cancer Institute | 0.281738 |
| clinical trials | 0.768713 |
| small bowel | 0.209407 |
| cancer information summary | 0.278324 |
| clinical trial | 0.582681 |
|
| new treatment | 0.286343 |
| small intestine adenocarcinoma | 0.324343 |
| External radiation therapy | 0.208562 |
| patients | 0.225884 |
| Blood. The cancer | 0.205393 |
| large intestine | 0.315511 |
| treatment clinical trial | 0.212129 |
| NCI PDQ cancer | 0.228818 |
| cancer research process | 0.201049 |
| new anticancer drugs | 0.248329 |
| cancer clinical trials | 0.271351 |
| lymph nodes | 0.209989 |
| tumor | 0.247188 |
| radiation therapy | 0.498101 |
| Treatment Editorial Board | 0.224109 |
| cancer information summaries | 0.209407 |
| small intestine cancer | 0.951217 |
| comprehensive cancer information | 0.20938 |
| standard treatment | 0.222923 |
|
CLICK HERE |
| 1791 |
National Cancer Institute |
Html |
es |
Fatiga (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de la fatiga, una afección caracterizada por extremo cansancio e incapacidad para funcionar por la falta de energía, que a menudo se observa como una complicación del cáncer y su tratamiento. |
| siguientes procedimientos | 0.385633 |
| anemia.Los análisis | 0.341771 |
| siguientes elementos | 0.380985 |
| descanso ayuda | 0.330891 |
| suficientes glóbulos | 0.429586 |
| siguientes hábitos | 0.360426 |
| fatiga mejora | 0.961013 |
| siguientes razones | 0.406276 |
| Mayor sentimiento | 0.336513 |
| causa anemia | 0.447908 |
| Más capacidad | 0.391264 |
| siguientes beneficios | 0.36204 |
| perÃodo intermedio | 0.361444 |
| terapia ayuda | 0.331417 |
| largo plazo | 0.508126 |
| menor cantidad | 0.379836 |
| suficiente oxÃgeno | 0.364828 |
| horarios regulares | 0.332634 |
| siguientes sÃntomas | 0.40531 |
| National Cancer Institute | 0.337934 |
| siguientes riesgos | 0.339715 |
| Mejor calidad | 0.332342 |
|
| paciente formas | 0.386322 |
| Terapia respiratoria | 0.332012 |
| vitamina b12 | 0.347342 |
| Instituto Nacional | 0.366294 |
| insuficiente cantidad | 0.340569 |
| siguientes problemas | 0.399021 |
| suficientes calorÃas | 0.375086 |
| Insuficiente apoyo | 0.328686 |
| siguientes factores | 0.398895 |
| Physician Data Query | 0.439181 |
| suficientes alimentos | 0.42156 |
| mayores probabilidades | 0.359824 |
| PDQ Fatiga | 0.692467 |
| Mejor apetito | 0.341698 |
| PDQ Trastornos | 0.417003 |
| posibles causas | 0.332899 |
| siguientes medicamentos | 0.4009 |
| general aumenta | 0.350637 |
| desesperanza frente | 0.332953 |
| menudo causa sÃntomas | 0.432855 |
| paciente preste atención | 0.49209 |
|
CLICK HERE |
| 1824 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer epitelial de ovario, de trompas de Falopio y primario de peritoneo (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer epitelial de ovario, de trompas de Falopio y primario de peritoneo. |
| Obstet Gynecol | 0.328674 |
| adjuvant chemotherapy | 0.316668 |
| chemotherapy in ovarian | 0.322043 |
| prognostic factors | 0.308986 |
| pacientes portadores | 0.306542 |
| crecimiento infiltrante destructor | 0.31512 |
| American Cancer Society | 0.31686 |
| Breast Cancer Linkage | 0.317976 |
| Mol Cancer Ther | 0.309108 |
| estadio temprano cirugÃa | 0.310703 |
| Ovarian Cancer Registry | 0.325508 |
| Cancer Res | 0.30945 |
| Cancer Linkage Consortium | 0.317364 |
| ovarian cancer | 0.973902 |
| randomized trial | 0.311991 |
| FIGOa Estadio Definición | 0.307321 |
| ovarian carcinoma | 0.378303 |
| adjuvant chemotherapy in | 0.315561 |
| Natl Cancer Inst | 0.350243 |
| International Collaborative Ovarian | 0.315389 |
| Gynecologic Oncology Group | 0.347704 |
| Collaborative Ovarian Neoplasm | 0.316238 |
| Radner Familial Ovarian | 0.312567 |
| Gynecol Oncol | 0.326661 |
| patients with | 0.315269 |
|
| Metástasis peritoneales macroscópicas | 0.307056 |
| estadio iv | 0.341957 |
| estadio ii | 0.434604 |
| peritoneo estadio opciones | 0.310058 |
| Cancer Facts | 0.309636 |
| estadio ic | 0.320607 |
| estadio ib | 0.307072 |
| estadio ia | 0.317155 |
| Ovarian carcinoma diagnosis | 0.308469 |
| Oncology Group study | 0.306421 |
| Young RC | 0.307696 |
| familial ovarian cancer | 0.336296 |
| Brady MF | 0.306168 |
| estadio iia | 0.314327 |
| treated with cisplatin-based | 0.308377 |
| Clin Oncol | 0.327391 |
| Ovarian Neoplasm | 0.324824 |
| breast cancer | 0.321408 |
| in ovarian | 0.344499 |
| in ovarian neoplasm | 0.319834 |
| quimioterapia adyuvante versus | 0.306417 |
| estadio iii | 0.330381 |
| with cisplatin-based chemotherapy | 0.310441 |
| treated with | 0.312964 |
|
CLICK HERE |
| 1839 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores del sistema nervioso central en adultos (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores del sistema nervioso central en adultos. |
| carmustina versus | 0.548633 |
| malignant glioma | 0.86408 |
| WB Saunders Co | 0.553184 |
| American Cancer Society | 0.574098 |
| sumario tratamiento | 0.554962 |
| cuáles pacientes | 0.551482 |
| primary gliomas located | 0.577278 |
| idh1 mutation | 0.550619 |
| IDH2 mutations | 0.547874 |
| Radiation Therapy Oncology | 0.556783 |
| Radiat Oncol Biol | 0.675252 |
| central nervous system | 0.6889 |
| patients with | 0.664355 |
| Medical Research Council | 0.587686 |
| Brain Tumor Research | 0.559245 |
| Acta Neuropathol | 0.563339 |
| cerebral low-grade glioma | 0.542243 |
| diagnosed malignant glioma | 0.650146 |
| who classification | 0.562467 |
| Neuroimaging Clin | 0.54527 |
| chemotherapy with | 0.549687 |
| patients with glioblastoma | 0.549124 |
| tumor group study | 0.541376 |
| Organización Mundial | 0.549658 |
| Research Council Brain | 0.538383 |
|
| malignant glioma after | 0.544669 |
| Cancer Treatment | 0.573642 |
| Ohgaki H | 0.558609 |
| mortalidad posoperatoria | 0.540841 |
| patients with idh1 | 0.548495 |
| Bent MJ | 0.548927 |
| Therapy Oncology Group | 0.603297 |
| radioterapia posoperatoria | 0.576011 |
| BRAF V600E | 0.543097 |
| low-grade glioma | 0.559845 |
| primary malignant glioma | 0.547729 |
| conventional radiotherapy with | 0.572491 |
| National Cancer Institute | 0.578026 |
| radiotherapy with | 0.578973 |
| newly diagnosed malignant | 0.564043 |
| caracterÃsticas histológicas | 0.717766 |
| Radiation-induced malignant gliomas | 0.578762 |
| Clin Oncol | 0.624379 |
| sistema nervioso central | 0.979769 |
| brain tumor | 0.782394 |
| Oncol Biol Phys | 0.679866 |
| adult brain tumors | 0.545694 |
| Cancer Institute | 0.592793 |
| brain tumour | 0.610029 |
|
CLICK HERE |
| 1892 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de estómago (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de estómago. |
| siguientes procedimientos | 0.623574 |
| estadio iv | 0.777016 |
| siguientes aspectos | 0.573343 |
| proteÃna vegf | 0.350025 |
| siguientes afecciones | 0.419234 |
| genes her2 | 0.549019 |
| exploraciones tep | 0.370808 |
| siguientes tipos | 0.374337 |
| cuerpo llamada | 0.407415 |
| rayos x | 0.496347 |
| estadio ib | 0.603838 |
| estadio ia | 0.601417 |
| enlace drugs approved | 0.548214 |
| escáner tep | 0.371104 |
| ondas sonoras | 0.369553 |
| estómago her2 | 0.993806 |
| proteÃna her2 | 0.939635 |
|
| siguientes sÃntomas | 0.405764 |
| National Cancer Institute | 0.33929 |
| siguientes riesgos | 0.335926 |
| Instituto Nacional | 0.373632 |
| PDQ Tratamiento | 0.63434 |
| estadio iiia | 0.59215 |
| estadio iiic | 0.584608 |
| estadio iiib | 0.586796 |
| estadio iia | 0.603101 |
| estadio iib | 0.602062 |
| partes distantes | 0.357123 |
| Physician Data Query | 0.452253 |
| antÃgeno carcinoembrionario | 0.374755 |
| Prueba ACE | 0.36171 |
| siguientes sumarios | 0.457366 |
| siguientes pruebas | 0.405163 |
|
CLICK HERE |
| 3439 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de estómago (gástrico) (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de estómago (gástrico). |
| Visuals Online | 0.546235 |
| PDQ Exámenes | 0.690831 |
| siguientes efectos | 0.595148 |
| Physician Data Query | 0.831228 |
| siguientes afecciones | 0.665794 |
| Estados Unidos | 0.968946 |
| siguientes personas | 0.608962 |
| rayos x | 0.591974 |
| prevención revisa | 0.557627 |
|
| América Central | 0.603242 |
| principal causa | 0.614774 |
| información ayuda | 0.567593 |
| National Cancer Institute | 0.581719 |
| siguientes riesgos | 0.571014 |
| siguientes sumarios | 0.754212 |
| vitamina b12 | 0.617718 |
| Instituto Nacional | 0.653888 |
|
CLICK HERE |
| 4390 |
National Cancer Institute |
Html |
en |
Tobacco |
null |
| safe level | 0.460816 |
| death | 0.358553 |
| Monday | 0.354828 |
| throat | 0.333618 |
| cause | 0.328958 |
| stomach | 0.336801 |
| LiveHelp pop-up | 0.465489 |
| kidney | 0.330373 |
| acute myeloid leukemia | 0.608856 |
| Friday | 0.35571 |
| pancreas | 0.384789 |
| smoking | 0.405609 |
| harms | 0.335823 |
| tobacco | 0.963237 |
| damage DNA | 0.469968 |
| cessation counselors | 0.452946 |
| secondhand smoke | 0.632466 |
| chemicals | 0.330701 |
| cervix | 0.34121 |
| tobacco product | 0.60509 |
| a.m. | 0.346985 |
| types | 0.328829 |
|
| confidential information | 0.439568 |
| liver | 0.32937 |
| People | 0.42541 |
| cancer diagnosis | 0.44607 |
| p.m. | 0.346876 |
| environmental tobacco smoke | 0.826608 |
| substantial gains | 0.462279 |
| ET | 0.353868 |
| life expectancy | 0.459232 |
| lung | 0.329921 |
| tobacco products | 0.728115 |
| smokeless tobacco | 0.623945 |
| snuff | 0.336877 |
| mouth | 0.374264 |
| NCI quitline | 0.460061 |
| bladder | 0.333336 |
| colon | 0.333223 |
| cancers | 0.332967 |
| online | 0.346425 |
| cancer | 0.481797 |
| risk | 0.357987 |
| rectum | 0.343994 |
|
CLICK HERE |
| 16694 |
National Cancer Institute |
Html |
en |
Using Trusted Resources |
Information to help people evaluate the source and credibility of health information that they find in print or online. |
| health information publications | 0.57623 |
| medical library | 0.468332 |
| health care provider | 0.525342 |
| health information | 0.816796 |
| reputable sources | 0.472899 |
| online cancer information | 0.566643 |
| research journal | 0.468961 |
| medical credentials | 0.480401 |
| Local bookstores | 0.465602 |
| web address | 0.542919 |
| Social media sites | 0.525651 |
| personal social media | 0.523002 |
| American Society | 0.463271 |
| official Facebook page | 0.525821 |
| online medical journal | 0.526189 |
| gather information | 0.496052 |
| Online health information | 0.583998 |
| trustworthy content | 0.471688 |
| credible source | 0.478584 |
| exact same kind | 0.463002 |
| educational institution | 0.468599 |
| different points | 0.462708 |
| health history | 0.475507 |
| evidence-based information | 0.519837 |
|
| sources | 0.501557 |
| research credentials | 0.469047 |
| Drug Administration | 0.463656 |
| book online | 0.475614 |
| different body | 0.465806 |
| health information online | 0.591142 |
| Twitter accounts | 0.467298 |
| National Cancer Institute | 0.533494 |
| alternative medicine | 0.466042 |
| social media | 0.640507 |
| Federal Trade Commission | 0.517205 |
| medical information | 0.510795 |
| Complementary therapies | 0.46171 |
| personal information | 0.537771 |
| new research results | 0.519971 |
| Cancer Treatment Scams | 0.525934 |
| book offer | 0.46625 |
| medical journals | 0.535182 |
| products online | 0.470366 |
| Government agencies | 0.476589 |
| social media accounts | 0.610423 |
| original source | 0.543837 |
| information | 0.948691 |
| good ways | 0.467256 |
|
CLICK HERE |